SCHEMBL5452650

SCHEMBL5452650

Cc1nc2c(O)c(CCC(=O)c3cccs3)c(C(=O)N(C)C)cn2c1C

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 5/20 0.38
WNT3A P56704 4/20 0.38
HPGD P15428 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
LMNA P02545 2/20 0.38
PKM P14618 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
POLB P06746 4/20 0.38
ALDH1A1 P00352 4/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4994479 0.84 KMT2A (0.36) HPGDALDH1A1MEN1KMT2ANPC1
SCHEMBL5328510 0.83 CYP3A4 (0.36) CTNNB1WNT3AHPGDHTTHSD17B10
Bicarbonate SCHEMBL4976269 0.83 KMT2A (0.35) HPGDALDH1A1MEN1KMT2ANPC1
SCHEMBL5326473 0.82 MAPT (0.36) CTNNB1WNT3AHPGDLMNATSHR
SCHEMBL5324528 0.81 CXCR1 (0.36) KMT2ANPC1RAB9A
SCHEMBL5324524 0.81 CXCR1 (0.36) KMT2ANPC1RAB9A
Formic Acid SCHEMBL4976263 0.81 HSD11B1 (0.34) HPGDMAPK1HTTALDH1A1MEN1
SCHEMBL5333478 0.80 NPC1 (0.34) LMNANPC1RAB9AMAPTGAA
SCHEMBL5326603 0.76 CHEK1 (0.36)
Iodide SCHEMBL4975557 0.74 CHEK1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007141253-A1 PROCESS FOR THE PRODUCTION OF INTERMEDIATES FOR THE PREPARATION OF TRICYCLIC IMIDAZOPYRIDINES NYCOMED GMBH (DE) 2007-12-13 WO disclosed
US-20070066674-A1 Tricyclic imidzopyridines for use as gastric secretion inhibitors ALTANA PHARMA AG (DE) 2007-03-22 US disclosed
EP-1696921-A1 TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS Altana Pharma AG (DE) 2006-09-06 EP disclosed
WO-2005058325-A1 TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS ALTANA PHARMA AG (DE) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066674-A1 Tricyclic imidzopyridines for use as gastric secretion inhibitors GIPR, SLC10A2, GRPR CTNNB1 4728/4885WNT3A 4296/4885HPGD 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.